scholarly article | Q13442814 |
P356 | DOI | 10.1017/S1041610207005583 |
P698 | PubMed publication ID | 17565765 |
P2093 | author name string | Yuichi Hirose | |
Michael Woodward | |||
Terry Mitchell | |||
P2860 | cites work | Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia | Q24246379 |
Neuropathologic features of amnestic mild cognitive impairment | Q28238965 | ||
Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
Age-related memory decline: current concepts and future directions | Q34187606 | ||
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. | Q34244667 | ||
Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 | ||
Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful. | Q35472824 | ||
Disclosing a diagnosis of dementia: a systematic review | Q35646972 | ||
Anthropological contributions to the understanding of age-related cognitive impairment | Q36104979 | ||
Neuropathology of older persons without cognitive impairment from two community-based studies | Q38405842 | ||
FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment | Q38416277 | ||
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
Regulatory authorities review use of galantamine in mild cognitive impairment | Q42789972 | ||
Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease | Q44438340 | ||
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment | Q45292749 | ||
Sixteen-year longitudinal and time lag changes in memory and cognition in older adults | Q46228215 | ||
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia | Q48550309 | ||
Mild cognitive impairment: is it Alzheimer's disease or not? | Q48813562 | ||
Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. | Q50710981 | ||
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. | Q50758048 | ||
Living wills and the Mental Capacity Act: a postal questionnaire survey of UK geriatricians. | Q51922310 | ||
Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. | Q51930296 | ||
Mild cognitive impairment, amnestic type: an epidemiologic study. | Q51939291 | ||
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. | Q51939293 | ||
Selective decline in memory function among healthy elderly. | Q52034186 | ||
Neurologic function in the optimally healthy oldest old. Neuropsychological evaluation. | Q52060808 | ||
Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. | Q53270841 | ||
Mild cognitive impairment | Q57306293 | ||
Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study | Q57782154 | ||
Classification criteria for mild cognitive impairment: a population-based validation study | Q73371507 | ||
A survey of attitudes and knowledge of geriatricians to driving in elderly patients | Q77324462 | ||
FITTING MULTIVARIATE MODELS TO COMMUNITY DATA: A COMMENT ON DISTANCE-BASED REDUNDANCY ANALYSIS | Q104204719 | ||
P433 | issue | 1 | |
P921 | main subject | Australia | Q408 |
New Zealand | Q664 | ||
mild cognitive impairment | Q1472703 | ||
cognitive dysfunction | Q57859955 | ||
P304 | page(s) | 77-85 | |
P577 | publication date | 2007-06-13 | |
P1433 | published in | International Psychogeriatrics | Q15761572 |
P1476 | title | A survey of attitudes of clinicians towards the diagnosis and treatment of mild cognitive impairment in Australia and New Zealand. | |
P478 | volume | 20 |
Q50740755 | Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. |
Q99208504 | Biomarker counselling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer´s Disease Consortium survey |
Q38749838 | Cancer-induced cognitive impairment: practical solutions to reduce and manage the challenge |
Q36653357 | Caring for older adults with mild cognitive impairment: an update for nurses. |
Q36680478 | Community-dwelling older adults with memory loss: needs assessment |
Q34135724 | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions |
Q85951092 | Familiarity, knowledge, and preferences of family physicians regarding mild cognitive impairment |
Q40890218 | Five ethical questions involving Alzheimer's disease. |
Q34053221 | Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members |
Q37396071 | Screening for mild cognitive impairment: a systematic review |
Q48124401 | The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years |
Search more.